Merge Technologies makes management move
Merge Technologies makes management moveConnectivity and PACS firm Merge Technologies has named Joseph Gentile director of worldwide system sales. Gentile will manage the Milwaukee, WI, firm’s systems solution group, which provides medical
Merge Technologies makes management move
Connectivity and PACS firm Merge Technologies has named Joseph Gentile director of worldwide system sales. Gentile will manage the Milwaukee, WI, firms systems solution group, which provides medical connectivity products and medical information appliances and servers. The company expects Gentiles experience as vice president of sales of IMACS Medical, which created a networked data and information management system for cardiology, to help it boost its business.
In other Merge news, the company last month began shipping its second-generation medical image information server MergeARK to facilities in Europe. MergeARK is part of the firms MergeWorks suite of products, and has been upgraded to improve its storage, retrieval, and reprint capacities. MergeARKs hardware and operating system software are now based on Dell servers and Red Hat Linux version 6.0, respectively. Some of Merges European installations of MergeARK will include DRM-7000, a CD-R library from Pioneer that can store 670 CDs to provide data storage of more than 400 gigabytes.
© 2000 Miller Freeman, Inc., a United News & Media company
- Search again
- Homepage
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
